Modality
mAb
MOA
WEE1i
Target
CGRP
Pathway
Hedgehog
Endometrial CaASAngelman
Development Pipeline
Preclinical
~Jan 2012
→ ~Apr 2013
Phase 1
~Jul 2013
→ ~Oct 2014
Phase 2
~Jan 2015
→ ~Apr 2016
Phase 3
~Jul 2016
→ ~Oct 2017
NDA/BLA
~Jan 2018
→ ~Apr 2019
Approved
Jul 2019
→ Oct 2029
ApprovedCurrent
NCT07054108
1,087 pts·Endometrial Ca
2020-07→TBD·Not yet recruiting
NCT07364829
761 pts·AS
2019-07→2029-10·Recruiting
NCT05871565
1,707 pts·Angelman
2024-07→2026-05·Terminated
+1 more trial
4,833 total pts3 indications
CompletedCurrentUpcoming
Catalysts (2)
2026-05-071mo awayPh3 Readout· Angelman
2029-10-203.6y awayPh3 Readout· AS
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Recruit…
Approved
Not yet…
Approved
Recruit…
Approved
Termina…
Catalysts
Ph3 Readout
2026-05-07 · 1mo away
Angelman
Ph3 Readout
2029-10-20 · 3.6y away
AS
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07054108 | Approved | Endometrial Ca | Not yet recr... | 1087 | DOR |
| NCT07364829 | Approved | AS | Recruiting | 761 | PASI75 |
| NCT05871565 | Approved | Angelman | Terminated | 1707 | SeizFreq |
| NCT05946838 | Approved | AS | Recruiting | 1278 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 |